Notice of Results

RNS Number : 5413W
Cambridge Cognition Holdings PLC
20 August 2015
 

 

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

 

Notice of Results

Investor Results Presentations

 

Cambridge Cognition Holdings plc (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, will be reporting its interim results for the six months ended 30 June 2015 on Thursday 10 September 2015.

 

Analyst presentation

Steven Powell, Chief Operating Officer and Nick Walters, Chief Financial Officer will be hosting an analyst briefing on the day of results, Thursday 10 September 2015, at 9.30am at Walbrook PR, 4 Lombard Street, London, EC3V 9HD.

 

Investor results presentation

A briefing for all investors will take place on Monday 14 September 2015 at Rocket, 6 Adams Court, Old Broad Street, London, EC4N 1DX from 4.30pm for a 4.45pm start, and will be followed by drinks and canapés.

 

If you would like to register to attend either presentation, or require further information, please contact Lianne Cawthorne on +44(0)20 7933 8788 or email camcog@walbrookpr.com.

 

 

Enquiries:

 

Cambridge Cognition Holdings plc

www.cambridgecognition.com

Steven Powell, Chief Operating Officer

Tel: 01223 810 700

Nick Walters, Chief Financial Officer

 

 

 

finnCap Ltd (Nomad and Broker)

Tel: 020 7220 0500

Geoff Nash/Simon Hicks

(Corporate Finance)

Malar Velaigam

(Corporate Broking)

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or camcog@walbrookpr.com

Lianne Cawthorne

Mob: 07584 391 303

Paul McManus

Mob: 07980 541 893

     

 

 

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic  scientists  in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function.  In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing.  Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families. 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORBUGDICDBBGUC
UK 100

Latest directors dealings